Articles tagged with Alzheimer Disease
A genome-wide association study identified genetic signals linked to increased AD risk, including those associated with CRP and plasma lipid levels. The findings suggest that targeting these risk factors may help delay AD progression and could have significant societal implications.
A new study found that participating in civic activities with others can reverse the normal brain shrinkage associated with aging. Seniors who engaged in meaningful social activities showed significant increases in brain volume and improved memory function over two years.
A new Duke University study in mice found that immune cells consuming an important amino acid called arginine may contribute to the development of Alzheimer's disease. Blocking this process with a small-molecule drug prevented characteristic brain plaques and memory loss in mouse models, suggesting a potential new treatment strategy.
Researchers investigated the influence of low-frequency magnetic fields on neurodegenerative diseases, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The study found that exposure to these fields did not accelerate disease development or affect learning behavior in relevant mouse models.
A new imaging tool found a strikingly similar pattern of abnormal protein deposits in the brains of retired NFL players with concussions, which may help identify brain disorders like CTE. The study also shows differences in brain imaging patterns between concussed athletes and healthy individuals.
A new study published in Biological Psychiatry found that beta secretase inhibitors can impair synaptic plasticity and cognitive functions, highlighting the need for dose-dependent treatment. The researchers urge caution in dosing these inhibitors to balance safety and efficacy.
A review article published in Journal of Caffeine Research suggests that caffeine may be used to treat or prevent Alzheimer's disease by reducing beta amyloid plaque accumulation. The study identifies potential opportunities for using caffeine to slow the progression of Alzheimer's disease.
Researchers at Yale University have successfully restored memory and synaptic connections in Alzheimer's mice using the experimental cancer drug AZD05030. The treatment blocks damage caused by amyloid-beta plaques, a hallmark of Alzheimer's disease, and has led to the launch of human trials.
A new review of the amyloid-beta peptide, a key component of senile plaques in Alzheimer's disease, has been published in Chemical Reviews. The study combines experimental and theoretical aspects and provides a comprehensive state-of-the-art overview of research on this protein.
A new study from UTMB reveals that a single dose of immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The therapy targets toxic tau oligomers, which are also linked to amyloid beta levels.
A Mayo Clinic study of over 3,600 postmortem brains reveals that tau protein is the primary driver of cognitive decline and memory loss in Alzheimer's disease. Amyloid buildup, while toxic, does not play a major role in disease progression, according to researchers.
A new study by University of York researchers has identified novel steps in dementia progression, potentially leading to targeted therapies. The research focuses on the protein CHMP2B and its impact on synapses, which can cause overgrowth and contribute to cognitive decline.
A new diet, MIND, shows reduced risk of Alzheimer's by 35-53% in participants who adhered moderately well, with benefits from brain-healthy food groups and limits on unhealthy foods. Long-term consistent adherence is crucial for optimal protection.
A three-year project at Goethe University Frankfurt is investigating olive polyphenols to develop new functional food for the ageing society. The researchers aim to test whether these substances can protect against Alzheimer's disease and improve brain function.
Researchers developed a new brain image analysis method to track beta-amyloid plaque deposition in Alzheimer's disease, using positron emission topography (PET). The new approach, which uses cerebral white matter as a reference region, improves the tracking of amyloid changes and evaluates investigational treatments.
Researchers from the UPV/EHU have developed a novel speech-based system to detect early stages of Alzheimer's disease. The Automatic Spontaneous Speech Analysis (ASSA) technique measures various parameters, including pauses and speech patterns, to help diagnose the disease.
A study of over 1,200 cognitively normal individuals aged 30-95 found that men experienced worse memory decline and lower hippocampal volume than women, while APOE ?4 carriers had greater amyloid accumulation from age 70 onwards.
Researchers at UC San Diego have identified a gene variant in the SORL1 gene that may be used to predict people most likely to respond to an investigational therapy for Alzheimer's disease. The study found that variants of the gene confer some protection from AD and are associated with reduced beta amyloid peptide production in neurons.
A new study by UCLA researchers has shown the feasibility of a blood-based test for diagnosing Alzheimer's disease, offering a safer and more affordable alternative to current methods. The test uses blood protein panels to predict brain amyloidosis with modest accuracy.
Researchers at Johns Hopkins University found that a novel therapeutic approach using an existing drug reverses hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a condition that increases risk for Alzheimer's dementia. The therapy, calmed hyperactivity in the brain and improved memory performance.
A new natural treatment for Alzheimer's disease, withanamides, is being developed by Michigan State University. The compound has shown to protect brain cells from damage caused by the rogue protein BAP, which is a common factor in Alzheimer's progression.
A study led by Drs. Kelleher and Shen discovered that presenilin-1 mutations decrease gamma-secretase activity, leading to age-dependent death of neurons and neurodegeneration. The findings may transform the way scientists design drugs for inherited Alzheimer's disease.
Researchers found that seven severe mortality-associated diseases are less prevalent in long-lived family members than the general population. These include Alzheimer's, hip fracture, diabetes, depression, prostate cancer, heart failure, and chronic kidney disease.
Researchers at MGH and BWH identified the exact mechanism by which presenilin mutations in inherited Alzheimer's disease produce devastating effects. They found that these mutations decrease, rather than increase, function of the presenilin-1 protein and gamma-secretase enzyme.
A study published in Annals of the Rheumatic Diseases found that people with a history of gout have a 24% lower risk of developing Alzheimer's disease. The researchers analyzed data from over 3.7 million people and found this protective effect, possibly due to uric acid's antioxidant properties.
A recent study used CERAD neuropsychological test battery to monitor Alzheimer's disease progression and treatment effects. The results showed that the test battery was a well-functioning measure for follow-up use, but its clinical application may be limited due to time requirements.
A Vanderbilt University study associates poor heart function with an increased risk of developing dementia and Alzheimer's disease. Participants with decreased cardiac index were two to three times more likely to develop significant memory loss over a follow-up period.
Scientists have discovered that abnormal protein amyloid accumulates inside neurons of people as young as 20, which may contribute to Alzheimer's disease. The study found that this early accumulation leads to the formation of toxic clumps that damage and kill neurons.
Researchers found that deleting TREM2 receptor in mice with AD-like disease reduced plaque formation, brain inflammation, and improved neuron survival. Macrophages lacking TREM2 were more effective at clearing beta-amyloid aggregates, suggesting a potential role for the receptor in neurodegeneration.
Researchers found that a protein called TREM2 triggers the clearance of debris from the brain, which can contribute to neurological diseases. Triggering this protein may help slow the progression of conditions like Alzheimer's and multiple sclerosis.
A deficiency in GLUT1 protein worsens Alzheimer's disease symptoms by breaking down blood-brain barrier, while targeting this protein may help prevent the disease progression among those at risk. Researchers found that GLUT1 deficiency led to neuronal dysfunction and behavioral changes.
Researchers discovered a skin test that can detect abnormal proteins associated with Alzheimer's and Parkinson's diseases. The study used skin biopsies to compare patients' protein levels, revealing seven times higher tau protein levels for those with both conditions.
The Roadmap Epigenomics Project has released new annotations of the human genome, which may hold the key to understanding and combating diseases. By mapping epigenetic signatures associated with complex traits, researchers aim to better understand how genes change and develop effective treatments for Alzheimer's disease.
Researchers analyzed gene and epigenetic mark changes in a mouse model of Alzheimer's disease to understand the role of microglia and immune pathways in disease progression. They found conserved epigenomic signatures between mice and humans, suggesting a potential therapeutic target.
Researchers identified the microtubule-associated protein tau (MAPT) gene as a key player in Alzheimer's disease. Carriers of the deleterious MAPT allele are at increased risk for developing AD and experience accelerated brain atrophy.
A new study suggests that nicotine's metabolite cotinine amplifies the effect of acetylcholine, a primary chemical messenger involved in learning and memory, potentially providing therapeutic benefits for Alzheimer's and other memory disorders. Cotinine may also have synergistic effects with existing Alzheimer's therapies.
Researchers have identified a molecular chaperone that can break the critical cycle leading to Alzheimer's disease. The molecule, Brichos, inhibits secondary nucleation, preventing the formation of toxic oligomers and amyloid fibrils, which are hallmark of the disease.
Researchers at Emory University School of Medicine have discovered new Alzheimer's disease targets through proteomics, which may lead to a better understanding of the disease mechanism. They identified tangle-like structures that sequester proteins critical for RNA splicing in early stages of the disease.
A study found that increasing klotho levels can protect against learning and memory deficits in a mouse model of Alzheimer's disease, counteracting the effects of Alzheimer-related toxins. Klotho's benefits may be due to its effect on neurotransmitter receptors involved in learning and memory.
Researchers at USC's Keck School of Medicine have identified a promising avenue for treating Alzheimer's disease by rebalancing the immune response to clear toxic plaques from the brain. The study found that blocking a specific substance can activate an immune response to restore memory loss and brain cell damage.
Researchers found diverse genomic changes in single neurons from Alzheimer's patients, showing that over 90% of sporadic Alzheimer's disease brains display highly significant DNA increases. Neurons from patients with sporadic Alzheimer's disease were four times as likely to contain more than two copies of the Alzheimer's-linked gene APP.
SuperAgers, aged 80+, have distinct brain signatures with a thicker cortex, fewer tangles linked to Alzheimer's, and a higher supply of neurons related to social intelligence.
A Tel Aviv University study found that a mutated gene regulating over 400 proteins affects male and female brains differently, leading to sex-specific learning and memory differences. The research suggests analyzing men and women separately in clinical trials to find cures for diseases due to potential gender differences.
Researchers found that xanthohumol, a compound in hops, can protect neuronal cells from oxidative damage, potentially slowing the development of brain disorders like Alzheimer's and Parkinson's diseases. The study suggests xanthohumol could be a promising candidate for fighting neurodegenerative conditions.
The Alzheimer's Association has awarded nearly $4 million in new grants to support five Phase 1 and 2a clinical trials exploring innovative treatments for Alzheimer's disease. These grants will help bridge the gap in funding for early-phase clinical drug trials, supporting promising projects from academia and industry.
Researchers at Gladstone Institutes discovered a new memory regulator in astrocytes, which improved memory in healthy mice and prevented impairments in Alzheimer's disease models. The study suggests that targeting A2A adenosine receptors may offer a potential treatment for improving memory.
Researchers discovered that an anti-inflammatory protein can increase plaque formation in the brain by binding to amyloid-beta and accelerating its buildup. The study suggests that Alzheimer's treatment should be tailored to patients carrying specific APOE variants, such as APOE4, which is a major genetic risk factor for the disease.
A new study by UCLA researchers found that walnut consumption was associated with improved cognitive function in adults, regardless of age or ethnicity. The study suggests that eating a handful of walnuts daily could help improve cognitive health.
A USC study reveals that the brain's protective blood barrier becomes leaky with age, starting at the hippocampus, a critical learning and memory center. The findings suggest that brain scans may be able to detect changes in blood vessels before they cause irreversible damage leading to dementia.
Researchers at RIKEN found that preventing abnormal sugar attachment to BACE1 enzyme reduces Alzheimer's plaques and improves cognitive performance in mice. This study reveals a novel mechanism for Alzheimer's disease development and potentially offers a new therapeutic target.
A new study suggests that depression and behavior changes can occur in people with Alzheimer's disease even before they experience memory problems. Researchers analyzed data from 2,416 participants and found that those who developed dementia were more likely to develop depression sooner than those without dementia.
A recent study published in Neurology found that depression and behavioral changes often occur before memory decline in people with Alzheimer's. Researchers analyzed data from over 2,400 participants and found that those who developed dementia were more likely to exhibit mood swings, including depression and delusions.
Researchers found that insulin nasal spray improved short-term verbal and visual information retention in adults with mild cognitive impairment and Alzheimer's. The study also showed significant benefits for those carrying the APOE-e4 gene, a risk factor for Alzheimer's.
Patients with neurodegenerative diseases, particularly behavioral variant of frontotemporal dementia, exhibit high rates of criminal behavior. The study found 8.5% of patients had a history of criminal behavior, with common offenses including theft, traffic violations, and public urination.
Researchers have developed a non-invasive MRI approach that can detect Alzheimer's disease in its earliest stages, identifying toxic amyloid beta brain toxins. The technique has the potential to improve diagnosis and treatment of the disease, which affects one out of nine people over 65.
A study found that mice lacking CXCR3 had reduced beta-amyloid plaque formation and attenuated behavioral deficits in a mouse model of Alzheimer's disease. The research suggests that activating the CXCR3 receptor could be an effective approach to treating AD.
A study suggests that early signs of cognitive decline are present in some individuals during midlife and are associated with cumulative exposure to modifiable risk factors. Elevated blood pressure and low physical activity over a 25-year period were found to be predictors of worse cognitive performance, even within the normal range.
Research participants who reported greater sleepiness had higher amyloid accumulation in cerebral cortex regions heavily affected in Alzheimer's disease. This suggests that sleep disturbance may be an early target for intervention to prevent cognitive deficits.
Researchers at Stanford University School of Medicine found that blocking a single molecule on microglia restored their function, reversing memory loss and other Alzheimer's-like features in mice. The study suggests that microglia play a crucial role in clearing A-beta protein clusters, which contribute to the disease's progression.
Researchers at Mainz University have discovered that a psoriasis medication may be effective in treating Alzheimer's disease by stimulating the activity of the enzyme ADAM10, which could lead to reduced accumulation of Alzheimer's plaques. The medication was well-tolerated and showed promise in enhancing learning and memory capacity.